A new clinical research programme at Philadelphia’s Mazzoni Center is putting LGBTQ+ health questions under the microscope. Its first trial is examining oral PrEP for people taking gender-affirming hormones, aiming to build evidence in an area where reassurance exists but focused research is limited. Here’s what the study is about, and what prospective participants should know.

Essential Takeaways

  • A first for the centre: Mazzoni Center launched its clinical research department in October and has begun its first trial.
  • The study’s focus: Researchers are assessing the safety and efficacy of oral PrEP for people using gender-affirming hormone therapy.
  • Why it matters: Existing guidance says PrEP and hormone therapy can be used together, but LGBTQ+ people have often been under-represented in health research.
  • Participation is voluntary: Mazzoni says patients can change their minds during a study without losing access to care.
  • More research is planned: The centre expects to launch further trials in spring 2027.

Mazzoni Center brings research into the care setting

Clinical research is moving closer to home for patients at Philadelphia’s Mazzoni Center. The organisation has launched a research department and begun a first trial, bringing the study of emerging healthcare options into a centre that serves LGBTQ+ communities.

The first study is examining oral pre-exposure prophylaxis, or PrEP, for transgender and gender-nonconforming people using gender-affirming hormone therapy. WHYY reports that researchers will look at both safety and efficacy, while also gathering information about participants’ experiences.

Mazzoni Center’s announcement confirms the launch of its first clinical trial. The broader aim, as WHYY describes it, is to offer research opportunities within a familiar care setting and help address the historic under-representation of LGBTQ+ people in health studies.

Why study PrEP alongside hormone therapy?

There is already reassuring guidance on taking PrEP with hormone therapy. The US Centers for Disease Control and Prevention says there are no known drug conflicts between the two, and that they can be used at the same time.

But general reassurance and focused trial evidence aren’t quite the same thing. The University of California, San Francisco’s Gender Affirming Health Program also notes that evidence has not always included transgender people or the hormone formulations used in gender-affirming care. That gap helps explain why a study focused on these patients matters.

WHYY reports that clinicians can be left with evidence gaps when LGBTQ+ people are under-represented in research. Building knowledge with the communities concerned could help make future care decisions better informed, rather than relying only on findings from other populations.

What participants should know before joining

Taking part in clinical research is a choice, not an obligation. The National Institute of Mental Health says prospective participants should receive information about a study, including its possible risks and benefits, and have the chance to ask questions before deciding. Consent is ongoing, and participants can stop taking part.

Mazzoni Center says patients in its research retain the right to change their minds without losing access to care or being penalised. Its privacy notice also says research participation is voluntary and won’t affect care, while setting out how health information may be used for research under applicable rules.

The centre says study data are anonymised, with access to information that can link a participant to their records limited to their own care provider at Mazzoni. Anyone considering the trial should check the study’s own consent and privacy materials with the research team, so they understand exactly how their information will be handled.

More LGBTQ+ health studies are on the way

The first trial has a relatively small number of places, and Mazzoni is screening its current patients rather than expecting to recruit broadly for this study. Still, WHYY reports that the centre sees it as the start of a wider research programme, with further studies expected as the department grows.

The centre plans to launch more trials in spring 2027. Its leaders also want research priorities to reflect questions raised by patients, staff and the community, rather than treating research as something separate from everyday care.

For readers interested in future opportunities, Mazzoni says the most direct route for now is to ask a provider at an upcoming appointment. The programme is still developing, but it points towards a useful shift: research shaped around the people it aims to serve.

It’s a promising step towards making LGBTQ+ health evidence more representative and useful.

Source Reference Map

Story idea inspired by: [1]

Sources by paragraph: